Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe ...

Pharming Group N.V., a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases, announces that the board of directors ...

Zeit Aktuelle Nachrichten 21.01. Pharming Group N.V.: Pharming Group to convene Extraordinary General Meeting of Shareholders 21.01. Pharming Group N.V. - 6-K, Report of foreign issuer 21.01 ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General Meeting of ...

Dutch biotech Pharming Group (Euronext: PHARM) today announced that its board of directors has nominated Fabrice Chouraqui to become the company’s new executive director and chief executive, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate. The price of PRVs, which can be used to shorten ...

At close: January 28 at 4:00:00 PM EST ...